Theravance Biopharma (TBPH) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Theravance Biopharma Revenue Highlights

Latest Revenue (Y)

$107.46M

Latest Revenue (Q)

$19.99M

Main Segment (Y)

Collaborative Arrangement Revenue

Main Geography (Y)

UNITED STATES

Theravance Biopharma Revenue by Period

Theravance Biopharma Revenue by Year

Date	Revenue	Change
2025-12-31	$107.46M	66.92%
2024-12-31	$64.38M	12.12%
2023-12-31	$57.42M	11.84%
2022-12-31	$51.35M	-7.17%
2021-12-31	$55.31M	-23.03%
2020-12-31	$71.86M	-2.12%
2019-12-31	$73.41M	21.61%
2018-12-31	$60.37M	292.37%
2017-12-31	$15.39M	-68.37%
2016-12-31	$48.65M	15.48%
2015-12-31	$42.13M	260.42%
2014-12-31	$11.69M	5071.68%
2013-12-31	$226.00K	-99.83%
2012-12-31	$130.15M	776.16%
2011-12-31	$14.85M	-

Theravance Biopharma generated $107.46M in revenue during NA 2025, up 66.92% compared to the previous quarter, and up 149.55% compared to the same period a year ago.

Theravance Biopharma Revenue by Quarter

Date	Revenue	Change
2025-09-30	$19.99M	-23.69%
2025-06-30	$26.20M	70.23%
2025-03-31	$15.39M	-17.95%
2024-12-31	$18.75M	11.18%
2024-09-30	$16.87M	18.32%
2024-06-30	$14.26M	-1.70%
2024-03-31	$14.50M	-17.43%
2023-12-31	$17.57M	11.93%
2023-09-30	$15.69M	14.14%
2023-06-30	$13.75M	31.99%
2023-03-31	$10.42M	-28.89%
2022-12-31	$14.65M	17.65%
2022-09-30	$12.45M	12.68%
2022-06-30	$11.05M	-16.26%
2022-03-31	$13.20M	-11.71%
2021-12-31	$14.95M	13.28%
2021-09-30	$13.19M	2.17%
2021-06-30	$12.91M	-9.42%
2021-03-31	$14.26M	-23.88%
2020-12-31	$18.73M	2.59%
2020-09-30	$18.26M	21.65%
2020-06-30	$15.01M	-24.44%
2020-03-31	$19.86M	-32.67%
2019-12-31	$29.50M	137.38%
2019-09-30	$12.43M	-52.48%
2019-06-30	$26.15M	389.88%
2019-03-31	$5.34M	-66.08%
2018-12-31	$15.74M	22.58%
2018-09-30	$12.84M	-45.31%
2018-06-30	$23.48M	182.20%
2018-03-31	$8.32M	84.25%
2017-12-31	$4.51M	5.61%
2017-09-30	$4.28M	21.83%
2017-06-30	$3.51M	13.67%
2017-03-31	$3.09M	-45.77%
2016-12-31	$5.69M	-70.16%
2016-09-30	$19.07M	248.66%
2016-06-30	$5.47M	-70.28%
2016-03-31	$18.41M	372.90%
2015-12-31	$3.89M	-63.61%
2015-09-30	$10.70M	49.96%
2015-06-30	$7.13M	-65.03%
2015-03-31	$20.40M	1323.66%
2014-12-31	$1.43M	-77.38%
2014-09-30	$6.34M	113.05%
2014-06-30	$2.97M	214.71%
2014-03-31	$945.00K	440.00%
2013-12-31	$175.00K	629.17%
2013-09-30	$24.00K	380.00%
2013-06-30	$5.00K	-77.27%
2013-03-31	$22.00K	-

Theravance Biopharma generated $19.99M in revenue during Q3 2025, up -23.69% compared to the previous quarter, and up 140.22% compared to the same period a year ago.

Theravance Biopharma Revenue Breakdown

Theravance Biopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Milestone	$25.00M	-	-	-	-
Collaborative Arrangement Revenue	$74.96M	-	-	-	-
License	$7.50M	-	-	-	-
YUPELRI Monotherapy	-	$83.52M	$77.34M	$19.50M	-
Collaboration revenue	-	$64.38M	$57.21M	$48.65M	-
Licensing revenue	-	-	-	$2.50M	-
Viatris collaboration agreement	-	-	-	$48.62M	$43.85M
Collaborative revenue	-	-	-	-	$11.46M

Theravance Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Collaborative Arrangement Revenue (69.76%), Milestone (23.26%), and License (6.98%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
YUPELRI Monotherapy	$24.70M	$23.22M	$20.42M	$23.34M	$21.77M	$19.33M	$21.23M	$19.30M	$16.40M	$18.70M	$17.20M	$15.30M	-	-	-	-	-	-	-	-
License	-	$7.50M	$7.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Revenue	-	$19.99M	$18.70M	$1.98M	$3.87M	$7.08M	$7.26M	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration revenue	-	-	-	$15.39M	$16.87M	$14.50M	$6.00K	$6.00K	$5.00K	$6.00K	-	-	-	-	-	-	-	-	-	-
Viatris collaboration agreement	-	-	-	-	-	-	-	-	$13.74M	$10.41M	$14.61M	$12.45M	$10.88M	$10.69M	$12.13M	$10.40M	-	-	-	-
Licensing revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.50M	-	-	-	-	-	-
Collaborative revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.00K	$2.81M	$2.80M	-	-	-	-
Nebulized T D4208	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$160.00M	$160.00M	-	-
Future Potential Combination Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$45.00M	$45.00M	-	-
Co Promote Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$10.93M	$10.38M	$11.65M	$11.00M

Theravance Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: YUPELRI Monotherapy (100.00%).

Theravance Biopharma Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
UNITED STATES	$74.96M	-	-	-	-
Europe	$32.50M	$223.00K	$222.00K	$38.00K	-
United States	-	$64.38M	$57.20M	$51.12M	$55.27M

Theravance Biopharma's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (69.76%), and Europe (30.24%).

Theravance Biopharma Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
GERN	Geron	$183.88M	$47.23M
DAWN	Day One Biopharmaceuticals	$158.18M	$39.80M
VALN	Valneva SE	$153.70M	$32.75M
GLUE	Monte Rosa Therapeutics	$123.67M	$23.19M
TBPH	Theravance Biopharma	$107.46M	$19.99M
VIR	Vir Bio	$68.56M	$240.00K
LENZ	LENZ Therapeutics	$19.09M	$5.00M
REPL	Replimune Group	-	-
TYRA	Tyra Biosciences	-	-
AVBP	ArriVent BioPharma	-	-

TBPH Revenue FAQ

What is Theravance Biopharma’s yearly revenue?

Theravance Biopharma's yearly revenue for 2025 was $107.46M, representing an increase of 66.92% compared to 2024. The company's yearly revenue for 2024 was $64.38M, representing an increase of 12.12% compared to 2023. TBPH's yearly revenue for 2023 was $57.42M, representing an increase of 11.84% compared to 2022.

What is Theravance Biopharma’s quarterly revenue?

Theravance Biopharma's quarterly revenue for Q3 2025 was $19.99M, a -23.69% decrease from the previous quarter (Q2 2025), and a 18.51% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $26.2M, a 70.23% increase from the previous quarter (Q1 2025), and a 83.75% increase year-over-year (Q2 2024). TBPH's quarterly revenue for Q1 2025 was $15.39M, a -17.95% decrease from the previous quarter (Q4 2024), and a 6.10% increase year-over-year (Q1 2024).

What is Theravance Biopharma’s revenue growth rate?

Theravance Biopharma's revenue growth rate for the last 3 years (2023-2025) was 87.14%, and for the last 5 years (2021-2025) was 94.29%.

What are Theravance Biopharma’s revenue streams?

Theravance Biopharma's revenue streams in c 25 are Milestone, Collaborative Arrangement Revenue, and License. Milestone generated $25M in revenue, accounting 23.26% of the company's total revenue Collaborative Arrangement Revenue generated $74.96M in revenue, accounting 69.76% of the company's total revenue License generated $7.5M in revenue, accounting 6.98% of the company's total revenue

What is Theravance Biopharma’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Theravance Biopharma was Collaborative Arrangement Revenue. This segment made a revenue of $74.96M, representing 69.76% of the company's total revenue.